Abstract

BackgroundAccurate evaluation of lymph node (LN) status is critical for determining the treatment options in patients with non-small cell lung cancer (NSCLC). This study aimed to develop and validate a 18F-FDG PET-based radiomic model for the identification of metastatic LNs from the hypermetabolic mediastinal–hilar LNs in NSCLC.MethodsWe retrospectively reviewed 259 patients with hypermetabolic LNs who underwent pretreatment 18F-FDG PET/CT and were pathologically confirmed as NSCLC from two centers. Two hundred twenty-eight LNs were allocated to a training cohort (LN = 159) and an internal validation cohort (LN = 69) from one center (7:3 ratio), and 60 LNs were enrolled to an external validation cohort from the other. Radiomic features were extracted from LNs of PET images. A PET radiomics signature was constructed by multivariable logistic regression after using the least absolute shrinkage and selection operator (LASSO) method with 10-fold cross-validation. The PET radiomics signature (model 1) and independent predictors from CT image features and clinical data (model 2) were incorporated into a combined model (model 3). A nomogram was plotted for the complex model, and the performance of the nomogram was assessed by its discrimination, calibration, and clinical usefulness.ResultsThe area under the curve (AUC) values of model 1 were 0.820, 0.785, and 0.808 in the training, internal, and external validation cohorts, respectively, showing good diagnostic efficacy for lymph node metastasis (LNM). Furthermore, model 2 was able to discriminate metastatic LNs in the training (AUC 0.780), internal (AUC 0.794), and external validation cohorts (AUC 0.802), respectively. Model 3 showed optimal diagnostic performance among the three cohorts, with an AUC of 0.874, 0.845, and 0.841, respectively. The nomogram based on the model 3 showed good discrimination and calibration.ConclusionsOur study revealed that PET radiomics signature, especially when integrated with CT imaging features, showed the ability to identify true and false positives of mediastinal–hilar LNM detected by PET/CT in patients with NSCLC, which would help clinicians to make individual treatment decisions.

Highlights

  • Lung cancer is still the leading cause of cancer-related mortality worldwide [1]

  • The occurrence of contralateral or multiregional mediastinal–hilar lymph node metastasis (LNM) in Non-small-cell lung cancer (NSCLC) might exclude the patient from primary surgery [3, 4], which is significantly associated with unfavorable clinical prognosis

  • The purpose of our study was to develop a predictive model that combined 18F-FDG PET radiomics features and conventional CT image features to identify true and false positives of mediastinal–hilar lymph node metastasis detected by positron emission tomography/computed tomography (PET/CT) in patients with NSCLC and to validate the predictive value of the model in an independent external data set

Read more

Summary

Introduction

Lung cancer is still the leading cause of cancer-related mortality worldwide [1]. Non-small-cell lung cancer (NSCLC) accounts for about 85% of lung cancers [2]. The occurrence of contralateral or multiregional mediastinal–hilar lymph node metastasis (LNM) in NSCLC might exclude the patient from primary surgery [3, 4], which is significantly associated with unfavorable clinical prognosis. Accurate lymph nodal staging is critical for determining the treatment options in patients with NSCLC for clinicians. Numerous studies have shown that intrathoracic nodal status is considered to be positive for metastatic spread if the activity of the node was higher than the mediastinal background [6,7,8]. Accurate evaluation of lymph node (LN) status is critical for determining the treatment options in patients with non-small cell lung cancer (NSCLC). This study aimed to develop and validate a 18F-FDG PET-based radiomic model for the identification of metastatic LNs from the hypermetabolic mediastinal–hilar LNs in NSCLC

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call